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Glutamate	 is	 believed	 to	 be	 the	 predominant	 excitatory	 neurotransmitter	 in	 the	 networks	
responsible	 for	 itch-related	 behavior.	 Beta-lactam	 antibiotics	 were	 shown	 to	 exert	
neuroprotective	 effects	 by	 increasing	 expression	 of	 the	 glutamate	 transporter	 GLT-1.	 We	
observed	whether	repeated	administration	of	the	beta-lactam	antibiotic	ceftriaxone	suppresses	
serotonin-induced	itch-related	behavior	(similarly	to	its	effect	on	pain	transmission)	in	mice.	
Chronic,	 but	not	 acute,	 ceftriaxone	 introductions	 reduced	 the	number	of	 serotonin-induced	
scratches;	dihydrokainic	acid,	a	selective	GLT-1	transporter	inhibitor,	partly	but	significantly	
abolished	this	effect	of	ceftriaxone.	Our	findings	suggest	that	GLT-1	activation	by	beta-lactam	
antibiotics	looks	promising	for	the	treatment	of	chronic	itch.
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INTRODUCTION
Glutamate	is	known	to	be	a	principal	excitatory	amino	
acid	 neurotransmitter	 in	 the	 CNS.	 A	 few	 glutamate	
transporters	 found	 in	 neuronal	 and	 glial	 membranes	
are	 primarily	 responsible	 for	 the	 regulation	 of	
extracellular	 glutamate	 homeostasis.	 Among	 these	
transporters,	glutamate	transporter-1	(GLT-1)	removes	
at	least	90%	of	extracellular	glutamate	and	appears	to	
play the pivotal role in terminating synaptic effects 
of	 this	 acid	 transmitter	 [1,	 2].	 Accordingly,	 drugs	
stimulating	 the	GLT-1	 expression	 are	 shown	 to	 offer	
neuroprotection	[3].	Among	these	agents,	ceftriaxone,	
a	 popular	 beta-lactam	 antibiotic,	 is	 being	 widely	
studied.	It	is	suggested	to	contribute	to	possible	effects	
in	many	clinical	CNS	disorders,	including	Parkinson’s	
disease,	 stroke,	 epilepsy,	 visceral	 and	 neuropathic	
pain,	and	tolerance	and	dependence	to	drugs	affecting	
the	CNS	 [3-9].	 In	 addition,	 it	 is	 under	 clinical	 trials	
for	the	treatment	of	amyotrophic	lateral	sclerosis.
Itch	is	an	unpleasant	(but	protective)	sensation	that	
provokes	the	desire	to	scratch.	Although	pain	and	itch	
are	distinct	sensations,	most	noxious	chemicals	appear	
to	 be	 nonspecific	with	 respect	 to	 these	 phenomena;	
moreover,	 spinal	 cord	 neuronal	 mechanisms	 are	
suggested	 to	play	a	pivotal	 role	not	only	 in	pain,	but	
also	 in	 itch	 [10,	11].	Recent	 researches	 showed	 that,	
similarly	to	pain	sensation,	glutamate	acts	as	the	major	
excitatory	transmitter	for	synaptic	transmission	in	the	
networks	involved	in	the	itch-related	behavior	[12].	As	
a	result,	the	directions	of	antipruritic	therapies	are	now	
expanding	from	the	periphery	 (skin)	 to	 the	CNS	[13,	
14].	Taking	into	consideration	the	similarities	between	
itch	and	pain	sensations,	we	investigated	the	effect	of	
activation	of	 the	GLT-1	transporter	by	ceftriaxone	on	
serotonin-induced	scratching	behavior	in	mice.
METHODS
Eight-	 to	 12-week-old	 male	 Balb/c	 mice	 (Center	 of	
the	 Laboratory	 Animals,	 Trakya	 University)	 were	
used	 in	 the	 experiments.	 Animals	 were	 maintained	
under	a	controlled	light	cycle	(12-12	h	light-dark)	and	
temperature	(21	±	2°C)	with	water	and	food	available	
ad libitum.	
To	 provoke	 scratching	 behavior,	 50	 µg/50	 µl	 of	
serotonin	was	 injected	 intradermally	 into	 the	 rostral	
part	of	the	back	of	the	experimental	mice.	Immediately	
after	 serotonin	 administration,	 the	 animals	were	 put	
back	 into	 the	 same	 cages,	 and	 their	 behavior	 was	
videotaped	 for	 30	min;	 the	 experimenters	 remained	
outside	the	laboratory	during	this	period.	The	number	
of	 scratching	 of	 the	 injected	 site	 by	 the	 hindpaws	
within	the	observation	period	was	counted	as	an	index	
of	the	scratching	intensity.
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Naive	mice	were	 i.p.	 injected	with	either	saline	or	
ceftriaxone	 (50,	 100,	 or	 200	mg/kg)	 once	 daily	 for	
7	 days.	On	 day	 7,	 scratching	 behavior	was	 induced	
by	serotonin	administration	30	min	after	ceftriaxone	
injection.	In	a	separate	animal	group,	a	single	injection	
of	ceftriaxone	 (200	mg/kg,	 i.p.)	was	administered	 in	
order	to	evaluate	its	acute	effect.	To	determine	if	GLT-1	 
activation	mediates	 the	ceftriaxone	effect,	 the	GLT-1	
blocker,	dihydrokainic	acid	 (DHKA,	10	mg/kg,	 i.p.),	
was	co-administered	with	ceftriaxone	for	7	days.	Drug	
doses	and	 treatment	 times	were	chosen	according	 to	
previous	reports	[5,	6,	15].	
A	commercial	preparation	of	ceftriaxone	(Rocephin,	
Roche,	France)	was	used;	DHKA	was	purchased	from	
Tocris	 (Great	Britain).	Ceftriaxone	and	DHKA	were	
dissolved	 in	saline	and	administered	 i.p.	 in	a	volume	
of	0.1	ml/10	g	body	mass.	
Analysis	of	variance	 (ANOVA)	was	used	 to	 carry	
out	statistical	comparisons	among	groups	and	followed	
by	 the	 Bonferroni	 t-test.	 Differences	 with	P values 
<	0.05	were	considered	to	be	statistically	significant.	
All	data	are	expressed	below	as	means	±	s.e.m.
RESULTS 
In	 the	 control	 group	 of	 serotonin-injected	 mice,	 the	
mean	 number	 of	 scratches	 within	 the	 30-min-long	
observation	 period	was	 46.6	±	 7.6	 (Fig.	 1,	 1).	 In	 the	
groups	 treated	 with	 50	 and	 100	 mg/kg	 ceftriaxone,	
the	 number	 of	 scratches	 was	 by	 about	 60%	 smaller	
than	in	 the	control	(P	<	0.05;	Fig.	1,	2	and	3).	 In	 the	
group	 treated	 with	 the	 greatest	 dose	 of	 ceftriaxone	 
(200	mg/kg),	the	intensity	of	suppression	of	scratching	
was	higher,	more	 than	 fourfold	 (P	<	0.01;	Fig.	1,	4).	
Single	 injections	 of	 200	mg/kg	 ceftriaxone	 provided	
some	trend	toward	decrease	in	the	number	of	scratches,	
but	 the	 difference	 from	 the	 control	was	 insignificant	
(Fig.	 1,	 5).	 Isolated	 injections	 of	 DHKA	 decreased	
somewhat	 the	 number	 of	 scratches.	 The	 decrement	
was	 about	 22%,	 but	 the	 difference	 was	 insignificant	
(mostly	 because	 of	 considerable	 interindividual	
dispersion	 of	 the	 values;	 Fig.	 1,	 6).	 Introductions	
of	 DHKA	 combined	 with	 chronic	 injections	 of	 high	
doses	 of	 ceftriaxone	 (200	 mg/kg)	 partly	 but	 rather	
significantly	 suppressed	 the	 protective	 effect	 of	 the	
above	antibiotic.	 In	 the	respective	group,	 the	number	
of	scratches	within	the	observation	interval	was	about	
60%	of	the	control,	i.e.,	the	intensity	of	scratching	was	
2.5	times	higher	than	in	the	group	chronically	treated	
with	200	mg/kg	ceftriaxone	but	with	no	action	of	 the	
above	GLT-1	transporter	inhibitor.	
Therefore,	 ceftriaxone	 introductions	 reduced	
serotonin-induced	 scratching	 behavior	 with	 all	 the	
doses	 used,	 but	 only	 under	 condition	 of	 repeated	
(chronic)	 injections.	 Certain	 dose	 dependence	 was	
observed	 in	 this	case;	 the	highest	doses	 (200	mg/kg)	
provided	the	greatest	anti-itch	effect;	at	the	same	time,	
the	dependence	at	smaller	doses	was	not	obvious.	The	
GLT-1	transporter	inhibitor	DHKA	(10	mg/kg)	elicited	
nearly	no	 action	 in	 the	 case	of	 isolated	 introduction	
but	 significantly	 abolished	 the	 inhibitory	 effect	 of	
ceftriaxone.	 No	 significant	 protective	 effect	 was	
observed	in	the	case	of	acute	ceftriaxone	treatment.	
DISCUSSION
Pain	and	itch	are	distinct	but,	at	the	same	time,	partly	
similar	sensations,	both	switching	on	the	alert	systems	
to	 protect	 the	 organism	 of	 vertebrates	 from	 some	
noxious	 stimuli.	 In	 the	 periphery,	 noxious	 chemicals	
are	not	very	specific	with	respect	to	pain	or	itch,	and	
TRP	channels	are	shown	 to	be	 involved	 in	mediating	
of	both	these	phenomena	[10,	16].	Distinct	subsets	of	
itch-specific	 C-fibers	 transmit	 signals	 from	 the	 skin	
to	 the	 superficial	 spinal	 dorsal	 horn	 regions	 [17,	 18]	
and,	 subsequently,	 to	 the	 thalamus	 and	 some	 other	
suprasegmental	structures	[11,	18].
Spinal	dorsal	horn	neuronal	networks	attract	great	
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Diagram	of	the	number	of	scratches	performed	by	serotonin-ijected	
mice	within	the	30-min-long	observation	period.	1-7)	Experimental	
groups,	control	(1),	repeatedly	injected	with	50,	100,	and	200	mg/kg	 
ceftriaxone	 daily	 during	 7	 days	 (2-4,	 respectively),	 subjected	 to	
single	 200	mg/kg	 ceftriaxon	 injections	 (5),	 to	 isolated	 10	mg/kg	
DHKA	injections	(6),	and	to	combined	repeated	injections	of	200	
mg/kg	ceftriaxone	and	10	mg/kg	DHKA	(7).	
Діаграма	 кількості	 чухальних	 рухів	 у	 мишей	 після	 ін’єкції	
серотоніну	протягом	30-хвилинного	періоду	спостереження.
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attention	of	researchers,	since	these	networks	are	sug-
gested	to	play	important	roles	in	the	formation	of	both	
pain	and	 itch	sensations	 [10,	11,	13].	Spinal	opioids,	
gastrin-releasing	peptide	 (GRP),	glutamate,	bradyki-
nin,	 substance	P,	 serotonin,	 and	 histamine	 receptors	
were	shown	(or	expected)	 to	be	 involved	 in	 itch,	and	
targeting	 these	 spinal	 receptors	 	by	pharmacological	
agents	 seems	promising	 for	 the	development	of	new	
antipruritic	drugs	[14].	In	addition,	first	inhibitory	in-
terneurons	 in	 itch-related	 networks	 have	 been	 iden- 
tified	in	the	dorsal	spinal	cord;	loss	or	suppression	of	
inhibition	has	been	shown	to	cause	pathological	 itch,	
similarly	 to	 abnormal	pain	 [19].	Deletion	of	vesicu-
lar	GLT-2	in	the	dorsal	root	ganglia	augmented	beha- 
vioral	 itch	 responses	 [20,	21].	Accordingly,	 similarly	
to	the	pain	sensation,	glutamate	is	proposed	to	be	the	
major	neurotransmitter	for	both	GRP-sensitive	and	in-
sensitive	itch-related	synaptic	transmission	in	the	spi-
nal	cord	[12].	
Chronic	 introductions	of	 	 ceftriaxone	were	 shown	
to	 exert	 anti-nociceptive	 effects	 in	neuropathic	 rats;	
the	 respective	events	were	considered	 resulting	 from	
specific	up-regulation	of	GLT-1	expression	in	the	spi-
nal	 cord	 [8].	When	 the	 importance	of	 the	 amount	of	
released	 glutamate	 in	 the	 spinal	 dorsal	 horn	 for	 the	
itch	phenomena	 is	 taken	 into	consideration,	 it	can	be	
speculated	that	isolated	action	of	DHKA	should	induce	
scratching	behavior.	However,	we	did	not	observe	such	
effect	after	isolated	administration	of	this	agent.	This	
may	 be	 related	 to	 an	 insufficient	 dose	 of	DHKA.	 It	
should	 also	 be	mentioned	 that	 the	 same	 dose	 of	 the	
above	drug	was	used	in	pain	studies	without	any	effect	
on	nociception	[4-6].
Thus,	we	 found	 that	 serotonin-induced	 scratching	
behavior	is	suppressed	due	to	repeated	treatment	with	
ceftriaxone.	 In	 addition	 to	 increased	 expression	 and	
function	of	the	GLT-1	in	the	brain,	chronic	ceftriaxone	
administration	may	also	provide	GLT-1	up-regulation	
in	the	spinal	dorsal	horn.	Although	the	mechanism	of	
anti-pruritic	activity	of	the	tested	beta-lactam	antibiotic	 
awaits	 further	 exploration,	 our	 results	 indicate	 that	
GLT-1	activation	by	this	agent	may	be	a	promising	op-
tion	in	pharmacotherapy	of	some	chronic	itch	states.
The	study	was	carried	out	in	accordance	with	the	statements	
of	 the	Council	Directive	 regarding	 the	 protection	 of	 animals	
used	 for	 experimental	 and	 other	 scientific	 purposes	 (86/609/
EEC,	1986,	Strasbourg).	 It	was	approved	by	 the	Animal	Care	
Ethics	 Committee	 at	 the	 Trakya	 University,	 and	 conducted	
according	 to	 the	 guidelines	 of	 the	 Ethical	 Committee	 of	 the	
International	Association	for	the	study	of	pain.
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Р	е	з	ю	м	е
Як	вважають,	глутамат	є	основним	збуджуючим	нейротранс-
мітером	у	нейронних	мережах,	відповідальних	за	поведін-
кові	моторні	прояви	при	почутті	 свербіжу.	β-лактамні	 ан-
тибіотики	мають	 нейропротективні	 властивості,	 оскільки	
забезпечують	посилену	експресію	глутаматного	транспор-
тера	GLT-1.	Ми	з’ясовували,	чи	здатне	повторне	введення	
β-лактамного	антибіотика	цефтриаксону	пригнічувати	ви-
кликані	 ін’єкціями	 серотоніну	 	 поведінкові	 моторні	 про- 
яви	(чухальні	рухи),	пов’язані	з	 індукцією	почуття	свербі-
жу	(подібно	до	впливу	цього	агента	на	біль)	у	мишей.	Хро-
нічні	(але	не	поодинокі)	введення	цефтриаксону	викликали	
зменшення	кількості	рухів	чухання.	Селективний	блокатор	
транспортера	GLT-1	 	дигідрокаїнова	кислота	частково,	але	
істотно	 перешкоджала	 цьому	 ефекту	 цефтриаксону.	Наші	
спостереження	дають	підстави	вважати,	що	активація	GLT-1	 
β-лактамними	антибіотиками	є	перспективним	підходом	у	
лікуванні	хронічного	свербіжу.	
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